SynthesisMolecular biotechnology2026
Efficacy and Safety of High-Dose Erythropoietin Combined with Hypothermia Therapy in Neonatal Hypoxic-Ischemic Encephalopathy: A Systematic Review and Meta-Analysis.
Synthesis in Molecular biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neonatal Hypoxic-Ischemic Encephalopathy: From the Limitations of Therapeutic Hypothermia to Precision Intervention.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study was conducted to systematically evaluate the effectiveness and safety of high-dose erythropoietin (EPO) combined with hypothermia in treating neonatal hypoxic-ischemic encephalopathy (HIE) using meta-analysis (MA) and providing insights for the clinical application of this treatment approach. Clinical randomized controlled trials on EPO combined with hypothermia for neonatal HIE were identified through computer searches of databases, including Chinese National Knowledge Infrastructure (CNKI), Web of Sciences, Embase, and PubMed up to May 20, 2024. Screening, data extraction, and quality assessment were independently performed by two researchers, with MA conducted using RevMan5.3. 12 studies involving 1562 infants were included. MA results indicated greatly lower odds in the EPO group (EG) versus the Control group (CG) for mortality, acute brain injury, intellectual developmental index < 70, and motor developmental index < 70 [odds ratio (OR) = 0.65, 95%CI = 0.47-0.91, p = 0.01; OR = 0.51, 95%CI = 0.25-1.01, p = 0.05; OR = 0.47, 95%CI = 0.22-1.00, p = 0.05; OR = 0.44, 95%CI = 0.20-1.00, p = 0.05]. EG and CG demonstrated neglectable differences in terms of hospital stay duration, renal failure/injury rate, incidence of neurological developmental abnormalities, and antiepileptic drug usage (p > 0.05). High-dose EPO combined with hypothermia in the treatment of neonatal HIE effectively reduced mortality rates and improved intellectual and motor developmental outcomes.
Indexed as
Identifiers
40146391What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.